Anyone that has traded biotechs knows that a CEO's opinion/word is of little consequence. They will do what they believe is in the best interest of their company and themselves. Sorry to sound jaded, but that is the reality of the situation. If it became apparent to the CEO that an RS was in the best interest, I do not think he would hesitate to do so. Getting wrapped up in a biotech is dangerous and it is important to remain objective and vigilant. CEO's of biotech companies are in some respect a salesman, they are not selling a product, they are selling the idea that their product will someday become successful. 100% speculation.
I would strongly caution one from basing their decisions based solely on the word of the CEO. Circumstances change and it is the responsibility of the CEO to adapt and make decisions that would further his company and shareholder interests. These are not gentlemen buying cows over a handshake, these are businessmen advancing interests.
With that being said, ONCS does have 200 million shares outstanding. While not huge, it's a large number of shares and IMO a R/S will occur sometime in the future, but this depends on partnerships. Depending on the time, it could be of little consequence and in fact the CEO stated that any news of a RS would be followed with a PR blitz. This does indicate that he has thought about the idea to some extent.
Either way, there is money to be made now and in the future. The key is to trade and invest smart. ONCS is severely undervalued and will take off in short order, but its important for an investor to never become to complacent.
All IMO
